Veracyte (VCYT) to Post Earnings on Thursday

Posted by on Jul 23rd, 2026

Veracyte (NASDAQ:VCYT – Get Free Report) is expected to be releasing its Q2 2026 results after the market closes on Thursday, July 30th. Analysts expect the company to announce earnings of $0.43 per share and revenue of $144.5950 million for the quarter. Interested persons can check the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, July 30, 2026 at 4:30 PM ET.

Veracyte (NASDAQ:VCYT – Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.52 EPS for the quarter, topping analysts’ consensus estimates of $0.34 by $0.18. The business had revenue of $139.07 million during the quarter, compared to analysts’ expectations of $130.36 million. Veracyte had a return on equity of 9.07% and a net margin of 16.25%.The business’s quarterly revenue was up 21.5% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.31 earnings per share. On average, analysts expect Veracyte to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Veracyte Trading Down 2.6%

Veracyte stock opened at $58.01 on Thursday. Veracyte has a 12-month low of $22.92 and a 12-month high of $60.91. The firm has a market capitalization of $4.63 billion, a price-to-earnings ratio of 53.22 and a beta of 1.93. The firm has a 50 day moving average of $51.89 and a 200 day moving average of $41.74.

Insider Activity at Veracyte

In other Veracyte news, CEO Marc Stapley sold 138,051 shares of the business’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $50.12, for a total value of $6,919,116.12. Following the completion of the sale, the chief executive officer directly owned 440,494 shares of the company’s stock, valued at $22,077,559.28. The trade was a 23.86% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider John Leite sold 13,975 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $50.07, for a total transaction of $699,728.25. Following the transaction, the insider directly owned 132,305 shares in the company, valued at approximately $6,624,511.35. This trade represents a 9.55% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 206,696 shares of company stock worth $10,079,058 over the last quarter. 1.60% of the stock is owned by insiders.

Institutional Trading of Veracyte

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Pacer Advisors Inc. boosted its holdings in shares of Veracyte by 229.1% in the 4th quarter. Pacer Advisors Inc. now owns 10,280 shares of the biotechnology company’s stock valued at $433,000 after buying an additional 7,156 shares in the last quarter. Corient Private Wealth LLC acquired a new position in shares of Veracyte during the fourth quarter worth $5,475,000. Fuller & Thaler Asset Management Inc. purchased a new stake in shares of Veracyte during the 4th quarter valued at $58,158,000. Empowered Funds LLC acquired a new stake in shares of Veracyte in the 4th quarter worth $42,000. Finally, XTX Topco Ltd purchased a new position in Veracyte during the 4th quarter worth $962,000.

Analysts Set New Price Targets

A number of analysts have recently issued reports on VCYT shares. Needham & Company LLC increased their price objective on shares of Veracyte from $48.00 to $57.00 and gave the stock a “buy” rating in a research note on Monday, June 1st. Piper Sandler began coverage on shares of Veracyte in a research note on Wednesday, July 15th. They issued an “overweight” rating and a $66.00 price target on the stock. Wolfe Research began coverage on Veracyte in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $55.00 price objective on the stock. UBS Group increased their target price on Veracyte from $48.00 to $52.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. Finally, Morgan Stanley boosted their price target on shares of Veracyte from $37.00 to $47.00 and gave the stock an “underweight” rating in a research report on Thursday, July 9th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $55.88.

View Our Latest Report on VCYT

Veracyte Company Profile

(Get Free Report)

Veracyte, Inc is a genomic diagnostics company focused on improving diagnostic accuracy and patient care through advanced molecular testing. Founded in 2008 and headquartered in South San Francisco, California, the company develops and commercializes minimally invasive genomic tests that aid in the diagnosis of thyroid, lung and other diseases. Veracyte’s proprietary platform analyzes gene expression patterns in clinical samples to help physicians make more informed treatment decisions, reducing unnecessary surgeries and improving patient outcomes.

The company’s flagship product, the Afirma Genomic Sequencing Classifier, is designed to assess thyroid nodules with indeterminate cytology, helping clinicians distinguish benign from suspicious nodules.

Featured Articles

Earnings History for Veracyte (NASDAQ:VCYT)

Receive News & Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related companies with MarketBeat.com's FREE daily email newsletter.